Harvard Bioscience, Inc.

Total Valuation

Harvard Bioscience, Inc. carries a market capitalization of 29.32M, placing it among publicly traded companies globally. Its enterprise value stands at 58.72M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Harvard Bioscience, Inc. currently has 4.51M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 0.25, and the price-to-book ratio stands at -0.10.

Enterprise Valuation

On an enterprise value basis, Harvard Bioscience, Inc. trades at an EV/EBITDA multiple of 9.39 and an EV/FCF ratio of 5.86. The EV/Sales ratio of 0.69 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 95.63 provides insight into valuation relative to core operating earnings.

Financial Position

Harvard Bioscience, Inc. maintains a current ratio of 1.99, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 439.20, indicating elevated leverage, while an interest coverage ratio of 1.07 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Stock Price Statistics

Harvard Bioscience, Inc.'s stock has gained approximately 54.3943% over the past 52 weeks. The 50-day moving average sits at 5.80, while the 200-day moving average is 5.63.

Income Statement

Over the trailing twelve months, Harvard Bioscience, Inc. generated 85.53M in revenue and converted that into -9.78M in net income, yielding earnings per share of -2.20. EBITDA reached 6.25M, while operating income came in at 614,000.00.

Balance Sheet

Harvard Bioscience, Inc. holds 7.10M in cash and equivalents against 44.12M in total debt, resulting in a net debt position of 29.11M. Total book value stands at -217.69M, with working capital of 23.62M providing operational flexibility.

Cash Flow

Harvard Bioscience, Inc. produced 3.08M in operating cash flow over the past twelve months. After subtracting -1.17M in capital expenditures, free cash flow totaled 1.91M - equivalent to 0.43 per share.

Margins

Harvard Bioscience, Inc. operates with a gross margin of 58.42, reflecting its pricing power and cost economics. The operating margin of 0.72 and net profit margin of -11.44 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Harvard Bioscience, Inc.'s most recent stock split took place on March 16, 2026 with a 10:1 split ratio.

Scores

Harvard Bioscience, Inc. posts an Altman Z-Score of -2.88, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.